These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38881076)

  • 21. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
    [No Abstract]   [Full Text] [Related]  

  • 22. Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer.
    Sanyal D; Majumder A; Ghosh S; Pandit K
    Diabetes Metab Syndr; 2021; 15(1):385-389. PubMed ID: 33548908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New fixed combination in type 2 diabetes].
    Red
    MMW Fortschr Med; 2016 Apr; 158(7):74. PubMed ID: 27071602
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
    Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
    BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
    Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
    Trials; 2020 May; 21(1):379. PubMed ID: 32370806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
    Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
    J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
    Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed-Dose Combination of Canagliflozin and Metformin as an Adjunct to Diet and Exercise in Indian Adults with Type 2 Diabetes Mellitus: Results from a Multicentric, Open-Label, Single-Arm, Phase IV Study.
    Magdum M; Unnikrishnan AG; Farishta F; Balamurugan R; Murthy S; Desai P; Singh KP; Barauh M; Rastogi A; Kesavadev J; Lakhani P; Panchal S; Korde T; Acharya R; Dixit J
    J Assoc Physicians India; 2024 Apr; 72(4):13-20. PubMed ID: 38881077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
    Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
    Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
    Kim J; Park S; Kim H; Je NK
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium-glucose cotransporter 2 inhibitor: a retrospective database study.
    Lautsch D; Iglay K; Yang L; Bansal N; Markan R; Kathe N; Rajpathak S
    Curr Med Res Opin; 2020 Oct; 36(10):1583-1589. PubMed ID: 32866052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
    Hu J; Zou P; Zhang S; Zhou M; Tan X
    Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
    Rupprecht H
    MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
    [No Abstract]   [Full Text] [Related]  

  • 39. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nicolle LE; Capuano G; Fung A; Usiskin K
    Postgrad Med; 2014 Jan; 126(1):7-17. PubMed ID: 24393747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.